Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.
Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P; CETLAM and PETHEMA Groups. Vives S, et al. Among authors: arnan m. Cancers (Basel). 2024 Nov 30;16(23):4028. doi: 10.3390/cancers16234028. Cancers (Basel). 2024. PMID: 39682214 Free PMC article.
A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Velázquez T, Arnán M, Vives S, Serrano J, Bernal T, Martínez-Sánchez P, Tormo M, Rodríguez-Medina C, Herrera-Puente P, Lavilla-Rubira E, Boluda B, Acuña-Cruz E, Cano I, Cáceres S, Ballesteros J, Falantes J, Martínez-Cuadrón D, Pérez-Simón JA, Montesinos P; PETHEMA Group. Rodríguez-Arbolí E, et al. Among authors: arnan m. Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618. Online ahead of print. Cancer. 2024. PMID: 39476204
Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial.
Laporte-Amargos J, Carmona-Torre F, Huguet M, Puerta-Alcalde P, Rigo-Bonnin R, Ulldemolins M, Arnan M, Del Pozo JL, Torrent A, Garcia-Vidal C, Pallarès N, Tebé C, Muñoz C, Tubau F, Padullés A, Sureda AM, Carratalà J, Gudiol C. Laporte-Amargos J, et al. Among authors: arnan m. Clin Microbiol Infect. 2024 Oct 19:S1198-743X(24)00488-9. doi: 10.1016/j.cmi.2024.10.006. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 39433124 Free article.
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Geissler K, Koristek Z, Del Castillo TB, Novák J, Rodríguez-Macías G, Metzelder SK, Illes A, Mayer J, Arnan M, Keating MM, Krauter J, Lunghi M, Fracchiolla NS, Platzbecker U, Santini V, Sano Y, Oganesian A, Keer H, Lübbert M. Geissler K, et al. Among authors: arnan m. Br J Haematol. 2024 Nov;205(5):1734-1745. doi: 10.1111/bjh.19741. Epub 2024 Sep 23. Br J Haematol. 2024. PMID: 39313917 Clinical Trial.
Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
Cellini A, Salvalaggio A, Velasco R, Arnan M, Cacciavillani M, Riva M, Trentin L, Pomares H, Lessi F, Briani C. Cellini A, et al. Among authors: arnan m. Leuk Lymphoma. 2024 Dec;65(13):2060-2063. doi: 10.1080/10428194.2024.2391899. Epub 2024 Aug 13. Leuk Lymphoma. 2024. PMID: 39138968 No abstract available.
Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis.
Xicoy B, Pomares H, Morgades M, Germing U, Arnan M, Tormo M, Palomo L, Orna E, Della Porta M, Schulz F, Díaz-Beya M, Esteban A, Molero A, Lanino L, Avendaño A, Hernández F, Roldan V, Ubezio M, Pineda A, Díez-Campelo M, Zamora L. Xicoy B, et al. Among authors: arnan m. Front Oncol. 2024 Jul 1;14:1385987. doi: 10.3389/fonc.2024.1385987. eCollection 2024. Front Oncol. 2024. PMID: 39011475 Free PMC article.
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Salamero O, Molero A, Pérez-Simón JA, Arnan M, Coll R, Garcia-Avila S, Acuña-Cruz E, Cano I, Somervaille TCP, Gutierrez S, Arévalo MI, Xaus J, Buesa C, Limón A, Faller DV, Bosch F, Montesinos P. Salamero O, et al. Among authors: arnan m. Lancet Haematol. 2024 Jul;11(7):e487-e498. doi: 10.1016/S2352-3026(24)00132-7. Epub 2024 May 30. Lancet Haematol. 2024. PMID: 38824932 Clinical Trial.
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Torres-Esquius S, Beas F, Chen-Liang TH, Pomares H, Santiago M, Varela ND, Liquori A, Hernandez F, Xicoy B, Hermosín L, Arnan M, Tazón-Vega B, Blanco A, Cervera J, Diez-Campelo M, Lozano ML, Valcárcel D, Bosch F, Montoro MJ, Jerez A; GESMD centres. Torres-Esquius S, et al. Among authors: arnan m. Br J Haematol. 2024 Aug;205(2):503-509. doi: 10.1111/bjh.19460. Epub 2024 Apr 19. Br J Haematol. 2024. PMID: 38639421
Biological basis of extensive pleiotropy between blood traits and cancer risk.
Pardo-Cea MA, Farré X, Esteve A, Palade J, Espín R, Mateo F, Alsop E, Alorda M, Blay N, Baiges A, Shabbir A, Comellas F, Gómez A, Arnan M, Teulé A, Salinas M, Berrocal L, Brunet J, Rofes P, Lázaro C, Conesa M, Rojas JJ, Velten L, Fendler W, Smyczynska U, Chowdhury D, Zeng Y, He HH, Li R, Van Keuren-Jensen K, de Cid R, Pujana MA. Pardo-Cea MA, et al. Among authors: arnan m. Genome Med. 2024 Feb 2;16(1):21. doi: 10.1186/s13073-024-01294-8. Genome Med. 2024. PMID: 38308367 Free PMC article.
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martínez-Banaclocha H, Hernández-Rivas JM, Marco-Ayala J, Martínez-Alarcón L, Linares-Latorre L, García-Ávila S, Amat-Martínez P, González T, Arnan M, Pomares-Marín H, Carreño-Tarragona G, Chen-Liang TH, Herranz MT, García-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrín P, Ferrer-Marín F. Hurtado-Navarro L, et al. Among authors: arnan m. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. Cell Rep Med. 2023. PMID: 38118408 Free PMC article.
98 results